These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 34944682)
1. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic. Mărginean CO; Meliț LE; Săsăran MO Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944682 [TBL] [Abstract][Full Text] [Related]
2. Lack of awareness and ethnic polarity is a major cause of metabolic associated fatty liver disease in high-risk diabetes population in South London. Ajaz S; Chamley M; Lok J; Soliman R; Khan R; Ahir K; Curtis M; Guerra-Veloz MF; Agarwal K Ther Adv Chronic Dis; 2024; 15():20406223241264539. PubMed ID: 39091507 [TBL] [Abstract][Full Text] [Related]
3. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Segura-Azuara NLÁ; Varela-Chinchilla CD; Trinidad-Calderón PA Front Med (Lausanne); 2021; 8():774079. PubMed ID: 35096868 [TBL] [Abstract][Full Text] [Related]
4. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. Le Garf S; Nègre V; Anty R; Gual P Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944730 [TBL] [Abstract][Full Text] [Related]
5. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Gutiérrez-Cuevas J; Santos A; Armendariz-Borunda J Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769060 [TBL] [Abstract][Full Text] [Related]
6. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Kjær MB; George J; Kazankov K; Grønbæk H Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486 [TBL] [Abstract][Full Text] [Related]
7. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health. Ramírez-Mejía MM; Díaz-Orozco LE; Barranco-Fragoso B; Méndez-Sánchez N Med Sci Monit; 2021 Aug; 27():e934134. PubMed ID: 34456329 [TBL] [Abstract][Full Text] [Related]
8. Low levels of Lysosomal Acid Lipase (LAL) activity increases necroinflammation in adult patients with biopsy-proven metabolic associated fatty liver disease. Thoen RU; Longo L; Neto SC; Álvares-da-Silva MR Clin Res Hepatol Gastroenterol; 2021 Nov; 45(6):101638. PubMed ID: 33662773 [TBL] [Abstract][Full Text] [Related]
9. Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children. Rupasinghe K; Hind J; Hegarty R J Pediatr Gastroenterol Nutr; 2023 Nov; 77(5):583-591. PubMed ID: 37592398 [TBL] [Abstract][Full Text] [Related]
10. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study. Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590 [TBL] [Abstract][Full Text] [Related]
11. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Yamamura S; Eslam M; Kawaguchi T; Tsutsumi T; Nakano D; Yoshinaga S; Takahashi H; Anzai K; George J; Torimura T Liver Int; 2020 Dec; 40(12):3018-3030. PubMed ID: 32997882 [TBL] [Abstract][Full Text] [Related]
12. Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge. Fouda S; Pappachan JM Endocrinol Metab Clin North Am; 2023 Sep; 52(3):xv-xvi. PubMed ID: 37495346 [TBL] [Abstract][Full Text] [Related]
13. New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease. Lin YC; Wu CC; Ni YH Front Pediatr; 2020; 8():603654. PubMed ID: 33363067 [TBL] [Abstract][Full Text] [Related]
14. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people. Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267 [TBL] [Abstract][Full Text] [Related]
15. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. Chen YL; Li H; Li S; Xu Z; Tian S; Wu J; Liang XY; Li X; Liu ZL; Xiao J; Wei JY; Ma CY; Wu KN; Ran L; Kong LQ BMC Gastroenterol; 2021 May; 21(1):212. PubMed ID: 33971822 [TBL] [Abstract][Full Text] [Related]
16. Review of current and new drugs for the treatment of metabolic-associated fatty liver disease. Gish R; Fan JG; Dossaji Z; Fichez J; Laeeq T; Chun M; Boursier J Hepatol Int; 2024 Oct; 18(Suppl 2):977-989. PubMed ID: 38850496 [TBL] [Abstract][Full Text] [Related]
17. Updates in fatty liver disease: Pathophysiology, diagnosis and management. Gofton C; George J Aust J Gen Pract; 2021 Oct; 50(10):702-707. PubMed ID: 34590082 [TBL] [Abstract][Full Text] [Related]
18. Circulating angiopoietin-like proteins in metabolic-associated fatty liver disease: a systematic review and meta-analysis. Ke Y; Liu S; Zhang Z; Hu J Lipids Health Dis; 2021 May; 20(1):55. PubMed ID: 34034750 [TBL] [Abstract][Full Text] [Related]
19. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease. Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799 [TBL] [Abstract][Full Text] [Related]
20. Liver fibrosis and MAFLD: the exploration of multi-drug combination therapy strategies. Dong Q; Bao H; Wang J; Shi W; Zou X; Sheng J; Gao J; Guan C; Xia H; Li J; Kang P; Xu Y; Cui Y; Zhong X Front Med (Lausanne); 2023; 10():1120621. PubMed ID: 37153080 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]